Amicus Therapeutics competitors
Amicus Therapeutics Competitors include Sanofi Genzyme, Mast Therapeutics, Zogenix and Clinigen Group.
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases. |  Sanofi Genzyme Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. |  Zogenix Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology. |  Clinigen Group A specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time | |
Founding Date | Founding Date 2002 | Founding Date 1981 | Founding Date 1995 | Founding Date 2006 | Founding Date 2010 |
Type | Type Public | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cranbury Township, US HQ Puteaux, FR Munich, DE Amsterdam, NL Denham, GB | Locations Cambridge, US HQ | Locations San Diego, US HQ | Locations Emeryville, US HQ Windsor And Maidenhead, GB | Locations Burton upon Trent, GB HQ |
Employees | Employees 263 | Employees N/A | Employees 14133% increase | Employees 681% increase | Employees 465200% increase |
Valuation ($) | Valuation ($) 2 b | Valuation ($) N/A | Valuation ($) 358.7 m | Valuation ($) 1.7 b | Valuation ($) 1.8 b |
Twitter followers | Twitter followers 793 | Twitter followers N/A | Twitter followers 873 | Twitter followers 475 | Twitter followers 1.2 k |
Financial ⚠ | |||||
Revenue (est.) | Revenue (est.) $36.9m (FY, 2017) | Revenue (est.) $5b (Y, 2017) | Revenue (est.) N/A | Revenue (est.) $9.8m (FY, 2017) | Revenue (est.) £302.3m (FY, 2017) |
Cost of goods | Cost of goods $6.2m (FY, 2017) | Cost of goods N/A | Cost of goods N/A | Cost of goods $10.7m (FY, 2017) | Cost of goods £179.6m (FY, 2017) |
Gross profit | Gross profit $30.7m (FY, 2017) | Gross profit N/A | Gross profit N/A | Gross profit ($908k) (FY, 2017) | Gross profit £122.7m (FY, 2017) |
Net income | Net income N/A | Net income N/A | Net income ($29.8m) (FY, 2017) | Net income ($126.8m) (FY, 2017) | Net income £3.8m (FY, 2017) |
Operating ⚠ | |||||
Countries | Countries N/A | Countries 100 (Sep, 2018) | Countries N/A | Countries N/A | Countries 43 (FY, 2016) |
For sources of this data, please see the company profileDownload Excel
View company profiles
Sanofi Genzyme
HQ
Cambridge, US
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.
View companyZogenix
HQ
Emeryville, US
Employees
68↑ 1% increase
Specialty pharmaceutical developing CNS and pain therapies and featuring DosePro needle free delivery technology.
View companyClinigen Group
HQ
Burton upon Trent, GB
Employees
465
A specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time
View company